VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.<\/p>\n
Vizimpro (dacomitinib tablets) for oral use\u00a0 Initial U.S. Approval: 2018
\nTo access dacomitinib tablets sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n","protected":false},"excerpt":{"rendered":"
Vizimpro (dacomitinib) is a medication used for the treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.<\/p>\n
Disease Indications-Lung Cancer If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cDacomitinib Tablets\u201d based on the information you provide.<\/strong><\/p>\n
\nManufacturer-Pfizer Limited
\nUsage-Oral
\nMedicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n